Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 119105102 | 11910510 | 2 | F | 2015 | 20160627 | 20160112 | 20160706 | EXP | US-SA-2015SA035264 | AVENTIS | 45.00 | YR | A | F | Y | 67.13000 | KG | 20160706 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 119105102 | 11910510 | 1 | PS | ALEMTUZUMAB | ALEMTUZUMAB | 1 | Intravenous (not otherwise specified) | 14-001372 | 103948 | 12 | MG | QD | |||||||
| 119105102 | 11910510 | 2 | SS | SOLU-MEDROL | METHYLPREDNISOLONE SODIUM SUCCINATE | 1 | Intravenous (not otherwise specified) | J00855 | 0 | 1 | G | QD | |||||||
| 119105102 | 11910510 | 3 | C | ACYCLOVIR. | ACYCLOVIR | 1 | Oral | 0 | 400 | MG | TABLET | BID | |||||||
| 119105102 | 11910510 | 4 | C | DIAZEPAM. | DIAZEPAM | 1 | Oral | 0 | 10 | MG | TABLET | Q8H | |||||||
| 119105102 | 11910510 | 5 | C | GABAPENTIN. | GABAPENTIN | 1 | Oral | 0 | 100 | MG | CAPSULE | TID | |||||||
| 119105102 | 11910510 | 6 | C | LANTUS | INSULIN GLARGINE | 1 | Subcutaneous | 100 UNIT/ML, SUBCUTANEOUS SOLUTION | 0 | ||||||||||
| 119105102 | 11910510 | 7 | C | MEPERIDINE | MEPERIDINE | 1 | Oral | Q4-6H | 0 | 50 | MG | TABLET | |||||||
| 119105102 | 11910510 | 8 | C | METFORMIN | METFORMIN HYDROCHLORIDE | 1 | Oral | 2 TABLETS DAILY | 0 | 500 | MG | TABLET | QD | ||||||
| 119105102 | 11910510 | 9 | C | METHYLPHENIDATE. | METHYLPHENIDATE | 1 | Oral | 1 TABLET DAILY | 0 | 20 | MG | TABLET | QD | ||||||
| 119105102 | 11910510 | 10 | C | METOPROLOL TARTRATE. | METOPROLOL TARTRATE | 1 | Oral | 1 TABLET DAILY | 0 | 100 | MG | TABLET | BID | ||||||
| 119105102 | 11910510 | 11 | C | VITAMIN D3 | CHOLECALCIFEROL | 1 | Oral | 0 | 5000 | IU | TABLET | ||||||||
| 119105102 | 11910510 | 12 | C | WARFARIN | WARFARIN | 1 | Oral | 1 TABLET DAILY | 0 | 4 | MG | TABLET | QD | ||||||
| 119105102 | 11910510 | 13 | C | ZOFRAN | ONDANSETRON HYDROCHLORIDE | 1 | Oral | 0 | 8 | MG | TABLET | QD | |||||||
| 119105102 | 11910510 | 14 | C | METOPROLOL SUCCINATE. | METOPROLOL SUCCINATE | 1 | Oral | 0 | 100 | MG | TABLET | BID | |||||||
| 119105102 | 11910510 | 15 | C | RITALIN | METHYLPHENIDATE HYDROCHLORIDE | 1 | Oral | 0 | 20 | MG | TABLET | QD | |||||||
| 119105102 | 11910510 | 16 | C | ASPIRIN. | ASPIRIN | 1 | Oral | 0 | 81 | MG | TABLET | QD | |||||||
| 119105102 | 11910510 | 17 | C | PROVIGIL | MODAFINIL | 1 | 1 IN MORNING | 0 | 200 | MG | |||||||||
| 119105102 | 11910510 | 18 | C | TIZANIDINE. | TIZANIDINE | 1 | 1-2 QHS | 0 | 4 | MG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 119105102 | 11910510 | 1 | Multiple sclerosis |
| 119105102 | 11910510 | 14 | Hypertension |
| 119105102 | 11910510 | 15 | Fatigue |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 119105102 | 11910510 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 119105102 | 11910510 | Dyspnoea | |
| 119105102 | 11910510 | Histoplasmosis disseminated | |
| 119105102 | 11910510 | Nausea | |
| 119105102 | 11910510 | Oxygen saturation decreased | |
| 119105102 | 11910510 | Pyrexia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 119105102 | 11910510 | 1 | 20150119 | 20150121 | 0 | |
| 119105102 | 11910510 | 2 | 20150119 | 20150121 | 0 |